Distal ventricular pacing and intraventricular gradient reduction for symptomatic relief in drug-refractory hypertrophic cardiomyopathy patients with mid-cavity obstruction

Queen Mary University of London0 sites25 target enrollmentJanuary 11, 2018

Overview

No summary available.

Registry

who.int

Start Date

January 11, 2018

End Date

May 31, 2022

Last Updated

4 years ago

Study Type

Interventional

Sex

All

Sponsor

•1\. Male or female, \>18 years
•2\. Referred for PPM \+/\- ICD implantation for either primary prevention of sudden cardiac death or other indications such as heart block or obstructive physiology
•3\. HCM patients with a mid\-cavity gradient of \=30 mmHg demonstrated by echocardiography and morphology confirmed by cardiac MRI. Gradient confirmed by cardiac catheterisation
•4\. All patients should be taking maximum tolerated doses of beta blockers or verapamil with or without disopyramide
•5\. Symptoms refractory to optimum medical therapy as above, for example breathlessness, chest pain, dizziness, or syncope

•1\. Patients with multi\-level obstruction, i.e. across the mid\-cavity and outflow tract
•2\. Patients with moderate or severe valvular stenosis or regurgitation due to primary valvular disease
•3\. Patients with untreated symptomatic coronary disease
•4\. Patients in atrial fibrillation at the time of implantation
•5\. Pregnancy
•6\. Renal failure with eGFR \< 20mL/min
•7\. Any patient not suitable in the clinicians opinion
•8\. Any patient who is for whatever reason is not expected for more than one year
•9\. Patients unable to provide informed consent